LPLUNC3 Inhibitors
LPLUNC3 inhibitors, also known as Long Palate, Lung, and Nasal Epithelium Clone 3 inhibitors, belong to a distinct chemical class of compounds designed to target and modulate the activity of the LPLUNC3 protein. LPLUNC3, a member of the PLUNC (Palate, Lung, and Nasal Epithelium Clone) family of proteins, plays a crucial role in various physiological processes within the human body. These inhibitors are engineered to specifically interact with LPLUNC3, either by binding to its active site or by disrupting its function, thereby altering its activity or expression levels.
The chemical structure of LPLUNC3 inhibitors can vary significantly, as they are designed to accommodate the specific molecular interactions required for effective inhibition. These compounds are meticulously crafted through medicinal chemistry approaches, focusing on the identification of key molecular targets within the LPLUNC3 protein and the development of small molecules or peptides capable of interfering with these targets. Researchers employ a combination of structure-activity relationship studies, high-throughput screening, and computational modeling to optimize the potency and selectivity of LPLUNC3 inhibitors.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol inhibits LPLUNC3 by binding to its active site, preventing its enzymatic activity. It disrupts the substrate binding, ultimately reducing its function in immune regulation and host defense. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $53.00 $88.00 | 6 | |
Ibuprofen acts as a non-selective COX inhibitor, indirectly affecting LPLUNC3 by suppressing pro-inflammatory prostaglandin production and mitigating the protein's inflammatory regulation. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone functions as a potent glucocorticoid receptor agonist, which suppresses LPLUNC3 activity by reducing the production of inflammatory mediators and cytokines. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate inhibits LPLUNC3 by interfering with the folic acid pathway, leading to decreased DNA and RNA synthesis and reducing immune system activation. | ||||||
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $102.00 | 6 | |
Hydrocortisone, a glucocorticoid, modulates LPLUNC3 function by suppressing immune system activity through anti-inflammatory mechanisms. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Omeprazole inhibits LPLUNC3 indirectly by suppressing gastric acid production, which can contribute to the regulation of inflammatory responses. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
Indomethacin is a non-selective COX inhibitor that inhibits LPLUNC3 by reducing prostaglandin synthesis, leading to anti-inflammatory effects. | ||||||
Nimesulide | 51803-78-2 | sc-200623 | 5 g | $72.00 | 1 | |
Nimesulide inhibits LPLUNC3 by selectively blocking COX-2, reducing the production of pro-inflammatory prostaglandins and attenuating immune responses. | ||||||
Naproxen | 22204-53-1 | sc-200506 sc-200506A | 1 g 5 g | $24.00 $41.00 | ||
Naproxen is a non-selective COX inhibitor that indirectly inhibits LPLUNC3 by reducing prostaglandin synthesis, leading to anti-inflammatory effects. | ||||||